Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 18 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Amifampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
improvement of fatigue measured by a decrease of EMIF-SEP score compared to placebo group.
43 months
Fatigue
Other measures (2)
evaluation of safety
43 months
Safetyquality of life impact
43 months
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 to 60
Inclusion Criteria: * Age >= 18 years and = \<60 years * Patients with multiple sclerosis clinically defined and with MIFS-SEP score > 44, without deficit sleep and without depression. * Patients without treatment by 3,4-DAP since 3 months * EDSS score \< 6 Exclusion Criteria: * ASAT/ALAT > 2 x ULN * MADRS >= 20 * Abnormality cardiac rhythm * Pregnancy * Asthma * Evolutive affection * Renal failure
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Rational of study : 3,4-diaminopyridine is suspected to improved the fatigue associated in patient's multiple sclerosis. In order to confirm this hypothesis, a randomized, controlled versus placebo, double blinded study is performed.
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- New strategies in neurological diseases
Phase 4 · Ongoing
Still running
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
- FAMILY
Completed
Result in a paper, not read yet
- Fampridine Study in Activities of Daily Living
Phase 4 · Completed
No result found
History
Started
Feb 2005
Main results due
Jun 2008
Finished
Jun 2008
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error